Peter J.M. Valk - Concepedia

Author

Peter J.M. Valk

Also Known As

Bob Löwenberg, L. Griskevicius, P J M Valk, P J Valk, P Valk, P. J. M. Valk, P. J. Valk, P. J.M. Valk, P. Valk, P.J. Valk

502

Publications

25K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Erasmus University Rotterdam Erasmus MC Cancer Institute Amsterdam UMC Location Vrije Universiteit Amsterdam University Medical Center Groningen

About

Peter J.M. Valk is an author at Erasmus MC specializing in medicine, cell biology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	42	56	11.2K
2	Health Sciences	19	19	3.5K
3	Natural Sciences	4	4	601
4	Public Health	3	3	99
5	Engineering	1	1	27

Peter J.M. Valk

159

Publications

22.9K

Citations

H-Index

Page 1

	Year	Citations
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation María E. Figueroa, Omar Abdel‐Wahab, Chao Lü, Cancer Cell Hematological MalignancySomatic VariantHypermethylation PhenotypeMedicineGenetics	2010	2.7K
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia Peter J.M. Valk, Roel G.W. Verhaak, M. Antoinette Beijen, New England Journal of Medicine	2004	1.4K
A 17-gene stemness score for rapid determination of risk in acute leukaemia Stanley Ng, Amanda Mitchell, Theodore A. Kennedy, Nature Hematological MalignancyAcute Leukaemia17-Gene Stemness ScoreRapid DeterminationMedicine	2016	887
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia María E. Figueroa, Sanne Lugthart, Yushan Li, Cancer Cell Hematological MalignancyChromatinEpigenetic ChangeGeneticsDna Methylation	2010	826
Molecular Minimal Residual Disease in Acute Myeloid Leukemia Mojca Jongen‐Lavrencic, Tim Grob, Diana Hanekamp, New England Journal of Medicine	2018	756
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia Stefan Gröschel, Mathijs A. Sanders, Remco M. Hoogenboezem, Cell ChromatinGeneticsGata2 DeregulationCancer GeneticsGene Expression	2014	696
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele, Blood Mixed-phenotype Acute LeukemiaPathologyMeasurable Residual DiseaseMyeloid NeoplasiaHematological Malignancy	2021	666
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Roel G.W. Verhaak, Chantal S. Goudswaard, Wim van Putten, Blood	2005	610
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Bas J. Wouters, Bob Löwenberg, Claudia Erpelinck-Verschueren, Blood	2009	572
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study Monique Terwijn, Wim L.J. van Putten, Angèle Kelder, Journal of Clinical Oncology	2013	444

Page 1